# AbbVie Inc.  Share Price Target ‘$184.08’, now 9.5% Upside Potential

- Link: https://www.directorstalkinterviews.com/abbvie-inc.share-price-target-184.08-now-9.5-upside-potential/4121164739
- Published: 2024-07-12T14:20:34+01:00
- Author: Charlotte Edwards

**AbbVie Inc.** which can be found using ticker (ABBV) now have 25 confirmed analysts
covering the stock with the consensus suggesting a rating of ‘buy’. The range between
the high target price and low target price is between $207.00 and $170.00 calculating
the mean target share price we have $184.08. (at the time of writing). Given that
the stocks previous close was at $168.14 this is indicating there is a potential
upside of 9.5%. There is a 50 day moving average of $164.95 and the 200 day MA is
$161.18. The company has a market cap of 300.04B. The current share price for the
company is: $169.91 USD

 The potential market cap would be $328,483,260,151 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 50.57, revenue per share of $30.78
and a 7.7% return on assets.

AbbVie Inc. (AbbVie) is a diversified research-based biopharmaceutical company. 
The Company is engaged in the research and development, manufacturing, commercialization
and sale of medicines and therapies. It offers products in various therapeutic categories,
including immunology products, which include Humira, Skyrizi and Rinvoq; oncology
products, which include Imbruvica and Venclexta/Venclyxto; aesthetics products that
include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience
products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; eye
care products, which consists of Lumigan/Ganfort, Alphagan/Combigan and Restasis,
and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella
and Synthroid. Its products are sold to wholesalers, distributors, government agencies,
health care facilities, specialty pharmacies, and independent retailers from the
AbbVie-owned distribution centers and public warehouses.

Share on: